Table 2

Comparison between Kawa-COVID-19 cohort and historical cohort in the Paris region

Historical cohort (n=220)Kawa-COVID-19 cohort (n=16)P value
Median age (IQR)2 (1.2 to 3.6)10 (4.7 to 12.5)<0.0001
Male gender128/220 (58%)8/16 (50%)0.63
Clinical features: n (%)
 Skin rash187/220 (85%)13/16 (81%)0.718
 Hands and feet erythema/oedema120/220 (54%)11/16 (68%)0.099
 Conjunctivitis176/220 (80%)15/16 (94%)0.342
 Dry cracked lips189/220 (85%)14/16 (87%)1
 Cervical lymphadenopathy114/220 (52%)6/16 (37%)0.309
Complete Kawasaki disease: n (%)142/220 (64%)10/16 (62%)1
Biological results: median (IQR)
 CRP (mg/L)142 (95 to 197)207 (162 to 236)0.006
 Platelets (G/L)383 (289 to 491)188 (164 to 244)<0.0001
 Lymphocytes (G/L)3.08 (1.86 to 4.77)1.15 (0.8 to 1.7)<0.0001
 Natraemia (mmol/L)135 (134 to 137)130 (127 to 134)0.0003
 Albumin (g/L)25 (22 to 28)21 (19 to 23)0.024
Echocardiography abnormalities: n (%)54/220 (26%)11/16 (69%)0.0004
 Myocarditis3/220 (1%)7/16 (44%)0.0001
 Coronary dilations42/220 (19%)3/16 (19%)1
 Pericarditis15/220 (7%)4/16 (25%)0.029
Resistance to single IVIg45/220 (20%)10/16 (62%)0.004
Origin:0.164
 Afro-Caribbean67/187 (36%)10/16 (62%)0.056
 Middle East44/187 (23%)2/16 (12%)0.532
 European48/187 (27%)4/16 (25%)1.0
 Asia28/187 (15%)0/160.136
  • CRP, C-reactive protein; IVIg, intravenous immunoglobulin.